FOURIER Opens ACC With a Bang

ACC Conference Reporter

ACC.17 | WASHINGTON, DC — Patients with atherosclerosis who had LDL cholesterol levels average 92 mg/dL or higher lowered their LDL by a mean of 59% by adding the PCSK9 inhibitor evolocumab (Repatha) and that reduction reduced their risk of heart attack, stroke and revascularization. Read More >>>

Keywords: ACC17, ACC Annual Scientific Session


< Back to Listings